New‐onset pemphigus foliaceus following SARS‐CoV‐2 infection and unmasking multiple sclerosis: A case report

Development of pemphigus foliaceus (PF) following SARS‐CoV‐2 infection has only been reported in one patient who had received Bamlanivimab and thus might be considered as a drug‐induced case of PF. Here, we reported the first case of PF arising solely after COVID infection without taking any culprit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohaghegh, Fatemeh, Hatami, Parvaneh, Refaghat, Arezoo, Mehdizadeh, Mohammadjavad, Aryanian, Zeinab, Mohandesi, Nessa Aghazadeh, Afshar, Zeinab Mohseni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165199/
https://www.ncbi.nlm.nih.gov/pubmed/35662780
http://dx.doi.org/10.1002/ccr3.5910
Descripción
Sumario:Development of pemphigus foliaceus (PF) following SARS‐CoV‐2 infection has only been reported in one patient who had received Bamlanivimab and thus might be considered as a drug‐induced case of PF. Here, we reported the first case of PF arising solely after COVID infection without taking any culprit drug.

Ejemplares similares